Skip to main content Skip to navigation
APC Mouse Anti-Human CD10
製品詳細
Down Arrow Up Arrow


BD™
MME; CALLA; EPN; NEP; neprilysin; SFE; atriopeptidase; enkephalinase
Human
Mouse BALB/c IgG1, κ
Acute CALLA Leukemia Blast Cells
Flow cytometry
25 μg/mL
5 μL
V CD10.7
4311
AB_400543
Phosphate buffered saline with gelatin and 0.1% sodium azide.
RUO (GMP)


Preparation and Storage

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

340923 Rev. 1
抗体の詳細
Down Arrow Up Arrow
HI10a

The CD10 antibody, clone HI10a, is derived from the hybridization of mouse P3-63-Ag8.653 myeloma cells with spleen cells of BALB/c mice immunized with blasts from a patient with acute CALLA leukemia.

The CD10 antibody recognizes a 100-kilodalton (kDa) type II transmembrane, glycosylated, zinc-containing metalloprotease. The CD10 antigen is also known as common acute lymphoblastic leukemia antigen (CALLA), neutral endopeptidase (NEP), gp100, and enkephalinase.

340923 Rev. 1
フォーマットの詳細
Down Arrow Up Arrow
APC
Allophycocyanin (APC), is part of the BD family of phycobiliprotein dyes. This fluorochrome is a multimeric fluorescent phycobiliprotein with excitation maximum (Ex Max) of 651 nm and an emission maximum (Em Max) at 660 nm. APC is designed to be excited by the Red (627-640 nm) laser and detected using an optical filter centered near 660 nm (e.g., a 660/20 nm bandpass filter). Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
APC
Red 627-640 nm
651 nm
660 nm
340923 Rev.1
引用&参考文献
Down Arrow Up Arrow
View product citations for antibody "340923" on CiteAb

Development References (19)

  1. Caligaris-Cappio F, Riva M, Tesio L, Schena M, Gaidano G, Bergui L. Human normal CD5+ B lymphocytes can be induced to differentiate to CD5- B lymphocytes with germinal center cell features.. Blood. 1989; 73(5):1259-63. (Biology). View Reference
  2. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
  3. Clinical and Laboratory Standards Institute. 2005. (Biology).
  4. Connelly JC, Chambless R, Holiday D, Chittenden K, Johnson AR. Up-regulation of neutral endopeptidase (CALLA) in human neutrophils by granulocyte-macrophage colony-stimulating factor.. J Leukoc Biol. 1993; 53(6):685-90. (Biology). View Reference
  5. Connelly JC, Skidgel RA, Schulz WW, Johnson AR, Erdös EG. Neutral endopeptidase 24.11 in human neutrophils: cleavage of chemotactic peptide.. Proc Natl Acad Sci USA. 1985; 82(24):8737-41. (Biology). View Reference
  6. Consolini R, Legitimo A, Rondelli R, et al. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).. Haematologica. 1998; 83(11):967-73. (Biology). View Reference
  7. Dworzak MN, Fritsch G, Fleischer C, et al. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow.. Leukemia. 1997; 11(8):1266-73. (Biology). View Reference
  8. Dworzak MN, Fritsch G, Fröschl G, Printz D, Gadner H. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny.. Blood. 1998; 92(9):3203-9. (Biology). View Reference
  9. Erdös EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones.. FASEB J. 1989; 3(2):145-51. (Biology). View Reference
  10. Erdös EG, Wagner B, Harbury CB, Painter RG, Skidgel RA, Fa XG. Down-regulation and inactivation of neutral endopeptidase 24.11 (enkephalinase) in human neutrophils.. J Biol Chem. 1989; 264(24):14519-23. (Biology). View Reference
  11. Greaves MF. Knapp W, ed. Leukemia Markers. New York, NY: Academic Press; 1981:19.
  12. Hann IM, Richards SM, Eden OB, Hill FG. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party.. Leukemia. 1998; 12(8):1249-55. (Biology). View Reference
  13. Hofman P, Selva E, Le Negrate G, et al. CD10 inhibitors increase f-Met-Leu-Phe-induced neutrophil transmigration.. J Leukoc Biol. 1998; 63(3):312-20. (Biology). View Reference
  14. LeBien TW, McCormack RT. The common acute lymphoblastic leukemia antigen (CD10)--emancipation from a functional enigma.. Blood. 1989; 73(3):625-35. (Biology). View Reference
  15. Letarte M, Vera S, Tran R, et al. Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase. J Exp Med. 1988; 168(4):1247-1253. (Biology). View Reference
  16. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood. 1987; 70(5):1316-1324. (Biology). View Reference
  17. Nadler LM, Korsmeyer SJ, Anderson KC, et al. B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation.. J Clin Invest. 1984; 74(2):332-40. (Biology). View Reference
  18. Salles G, Rodewald HR, Chin BS, Reinherz EL, Shipp MA. Inhibition of CD10/neutral endopeptidase 24.11 promotes B-cell reconstitution and maturation in vivo. Proc Natl Acad Sci USA. 1993; 90:7618-7622. (Biology).
  19. Zola H. CD10 Workshop Panel report. In: Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995:505-507.
すべて表示する (19) 表示項目を減らす
340923 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. 

 

Although not required, these products are manufactured in accordance with Good Manufacturing Practices.